Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Differential impact of lipid profile according to neutrophil-to-lymphocyte ratio status in patients with advanced cancer treated with immunotherapy.
Perrone F, Pecci F, Maffezzoli M, Giudice GC, Cognigni V, Mazzaschi G, Cantini L, Santamaria L, Paoloni F, Bruno Rocchi ML, Coriano' M, Acunzo A, Quaini F, Tiseo M, Kamal SS, Berardi R, Buti S. Perrone F, et al. Among authors: maffezzoli m. Immunotherapy. 2024;16(13):859-868. doi: 10.1080/1750743X.2024.2377953. Epub 2024 Aug 6. Immunotherapy. 2024. PMID: 39105618
Intersecting Blood Cytokines With Cholesterol Parameters to Profile Patients With Advanced Solid Tumors Receiving Immune Checkpoint Inhibitors.
Mazzaschi G, Perrone F, Maglietta G, Favari E, Verzè M, Pluchino M, Minari R, Pecci F, Gnetti L, Campanini N, Silini EM, De Filippo M, Maffezzoli M, Giudice GC, Testi I, Tiseo M, Quaini F, Buti S. Mazzaschi G, et al. Among authors: maffezzoli m. J Immunother. 2024 Nov-Dec 01;47(9):388-394. doi: 10.1097/CJI.0000000000000534. Epub 2024 Jul 11. J Immunother. 2024. PMID: 38989743 Free PMC article.
Analyses of tumor microenvironment in patients with advanced renal cell carcinoma receiving immunotherapy (Meet-URO 18 study).
Catalano F, Brunelli M, Signori A, Rescigno P, Buti S, Galli L, Spada M, Masini C, Galuppini F, Vellone VG, Gaggero G, Maruzzo M, Merler S, Vignani F, Cavo A, Bimbatti D, Milella M, Dei Tos AP, Sbaraglia M, Murianni V, Damassi A, Cremante M, Maffezzoli M, Llaja Obispo MA, Banna GL, Fornarini G, Rebuzzi SE. Catalano F, et al. Among authors: maffezzoli m. Future Oncol. 2024 May 3:1-19. doi: 10.1080/14796694.2024.2340960. Online ahead of print. Future Oncol. 2024. PMID: 38861289
Analyses of tumor microenvironment in patients with advanced renal cell carcinoma receiving immunotherapy (Meet-URO 18 study).
Catalano F, Brunelli M, Signori A, Rescigno P, Buti S, Galli L, Spada M, Masini C, Galuppini F, Vellone VG, Gaggero G, Maruzzo M, Merler S, Vignani F, Cavo A, Bimbatti D, Milella M, Dei Tos AP, Sbaraglia M, Murianni V, Damassi A, Cremante M, Maffezzoli M, Llaja Obispo MA, Banna GL, Fornarini G, Rebuzzi SE. Catalano F, et al. Among authors: maffezzoli m. Future Oncol. 2024;20(21):1495-1503. doi: 10.2217/fon-2023-1068. Epub 2024 Jun 12. Future Oncol. 2024. PMID: 38682738
Real World Analysis of Peritoneal Metastasis From Renal Cell Carcinoma. Meet-Uro27.
Stellato M, Buti S, Maruzzo M, Bassanelli M, Bersanelli M, Napoli MD, Dionese M, Fanelli M, Filippi R, Fotia G, Galli L, Grillone F, Maffezzoli M, Maiorano BA, Nasso C, Rebuzzi SE, Lalli L, Roviello G, Sorarù M, Vincenzi B, Procopio G, Verzoni E. Stellato M, et al. Among authors: maffezzoli m. Clin Genitourin Cancer. 2024 Jun;22(3):102078. doi: 10.1016/j.clgc.2024.102078. Epub 2024 Mar 19. Clin Genitourin Cancer. 2024. PMID: 38631104
External validation of a red cell-based blood prognostic score in patients with metastatic renal cell carcinoma treated with first-line immunotherapy combinations.
Maffezzoli M, Santoni M, Mazzaschi G, Rodella S, Lai E, Maruzzo M, Basso U, Bimbatti D, Iacovelli R, Anghelone A, Fiala O, Rebuzzi SE, Fornarini G, Lolli C, Massari F, Rosellini M, Mollica V, Nasso C, Acunzo A, Silini EM, Quaini F, De Filippo M, Brunelli M, Banna GL, Rescigno P, Signori A, Buti S. Maffezzoli M, et al. Clin Exp Metastasis. 2024 Apr;41(2):117-129. doi: 10.1007/s10585-024-10266-6. Epub 2024 Feb 16. Clin Exp Metastasis. 2024. PMID: 38363410 Free PMC article.
Prognostic Impact of Blood Lipid Profile in Patients With Advanced Solid Tumors Treated With Immune Checkpoint Inhibitors: A Multicenter Cohort Study.
Pecci F, Cantini L, Cognigni V, Perrone F, Mazzaschi G, Agostinelli V, Mentrasti G, Favari E, Maffezzoli M, Cortellini A, Rossi F, Chiariotti R, Venanzi FM, Lo Russo G, Galli G, Proto C, Ganzinelli M, Tronconi F, Morgese F, Campolucci C, Moretti M, Vignini A, Tiseo M, Minari R, Rocchi MLB, Buti S, Berardi R. Pecci F, et al. Among authors: maffezzoli m. Oncologist. 2024 Mar 4;29(3):e372-e381. doi: 10.1093/oncolo/oyad273. Oncologist. 2024. PMID: 37796838 Free PMC article.
Characterization of Tumor and Immune Tumor Microenvironment of Primary Tumors and Metastatic Sites in Advanced Renal Cell Carcinoma Patients Based on Response to Nivolumab Immunotherapy: Preliminary Results from the Meet-URO 18 Study.
Rebuzzi SE, Brunelli M, Galuppini F, Vellone VG, Signori A, Catalano F, Damassi A, Gaggero G, Rescigno P, Maruzzo M, Merler S, Vignani F, Cavo A, Basso U, Milella M, Panepinto O, Mencoboni M, Sbaraglia M, Dei Tos AP, Murianni V, Cremante M, Llaja Obispo MA, Maffezzoli M, Banna GL, Buti S, Fornarini G. Rebuzzi SE, et al. Among authors: maffezzoli m. Cancers (Basel). 2023 Apr 21;15(8):2394. doi: 10.3390/cancers15082394. Cancers (Basel). 2023. PMID: 37190322 Free PMC article.
13 results